Loading...
TORRENT PHARMA INC — Citalopram Import Profile: Suppliers, Formulations & Sources
Loading...
Pharmaceutical Importer · #2 buyer for Citalopram · $7.9M import value · 177 shipments · UNITED STATES · DGFT Verified
TORRENT PHARMA INC is the #2 importer of Citalopram from India with $7.9M in import value and 177 verified shipments. TORRENT PHARMA INC holds a 2.8% market share in Citalopram imports based in UNITED STATES. The company sources from 1 verified supplier across 101 formulations shipped to 1 country. Overall, TORRENT PHARMA INC imports 9 pharmaceutical products worth $41.5M across 6 therapeutic categories.
Verified from 177 customs shipment records
| Supplier | Value | Shipments | % Share |
|---|---|---|---|
| TORRENT PHARMACEUTICALS LIMITED | $7.9M | 177 | 100.0% |
TORRENT PHARMA INC sources Citalopram from 1 verified Indian supplier based on 177 customs records. The primary supplier is TORRENT PHARMACEUTICALS LIMITED accounting for 100.0% of imports.
Buyers ranked immediately above and below #2 by import value
| # | Buyer | Country | Import Value | Shipments | Avg/Shipment |
|---|---|---|---|---|---|
| 4 | YUSEN LOGISTICS BENELUX BELGIUM | BELGIUM | $8.9M | 179 | $50.0K |
| 2 | TORRENT PHARMA INC ★ | UNITED STATES | $7.3M | 145 | $50.0K |
| 7 | LEK S.A. | POLAND | $4.1M | 112 | $36.5K |
| 5 | AUROLOGISTICS LLC (AUROBINDO PHARMA | UNITED STATES | $3.9M | 78 | $50.0K |
TORRENT PHARMA INC ranks #2 among 736 Citalopram importers from India. Average shipment value of $50.0K compared to the market average of $74.5K. The closest competitors by value are YUSEN LOGISTICS BENELUX BELGIUM and LEK S.A..
Destination countries from 177 verified shipments
| Country | Value | Shipments | Share |
|---|---|---|---|
| UNITED STATES | $7.9M | 177 | 100.0% |
TORRENT PHARMA INC imports Citalopram to 1 country. The primary destination is UNITED STATES receiving 100.0% of shipments worth $7.9M.
| Formulation | Value | Shipments |
|---|---|---|
| ESCITALOPRAM TABLETS USP 20MG | $590.1K | 12 |
| OTHER - ESCITALOPRAM TABLETS USP 20MG (NDC NO. 13668-137-10) ( ESCITALOPRAM 20MG) NOS SIZE 1X1000 TABLETS | $450.0K | 9 |
| ESCITALOPRAM TABLETS USP 10 MG | $367.4K | 9 |
| OTHER - ESCITALOPRAM TABLETS USP 20MG (NDC NO. 13668-137-01) ( ESCITALOPRAM 20MG) NOS SIZE 1X1000 TABLETS | $300.0K | 6 |
| OTHER - ESCITALOPRAM TABLETS USP 10MG (NDC NO. 13668-136-10) (ESCITALOPRAM 10MG)NOS SIZE 1X1000 TABLETSNOS | $200.0K | 4 |
| OTHER - ESCITALOPRAM TABLETS USP 20MG (NDC NO.13668-137-10)( ESCITALOPRAM 20MG )NOS SIZE 1X1000 TABLETS | $200.0K | 4 |
| ESCITALOPRAM TABLETS USP 10MG | $150.0K | 3 |
| CITALOPRAM TABLETS USP 40MG | $150.0K | 3 |
What TORRENT PHARMA INC and other importers must comply with to import Citalopram from India
U.S. Food and Drug Administration (FDA)
Abbreviated New Drug Application (ANDA) for generic drugs, requiring bioequivalence studies and compliance with 21 CFR. Indian manufacturing sites must pass FDA pre-approval inspection.
Typical timeline: 10–18 months for ANDA approval
FDA cGMP compliance (21 CFR 210/211); facility inspection by FDA prior to approval
Visual overview of India's citalopram buyer profile for TORRENT PHARMA INC — top suppliers, destinations, pricing, and trade routes
India exported $54.8M worth of Citalopram through 7,372 shipments from 257 suppliers to 101 countries, serving 736 buyers globally. TORRENT PHARMA INC imports $7.9M of this total, accounting for 2.8% of India's Citalopram exports with 177 shipments from UNITED STATES. This is verified from 177 customs shipment records covering 101 distinct formulations.
TORRENT PHARMA INC's average Citalopram order value is $44.4K per consignment, based on 177 shipments totaling $7.9M. TORRENT PHARMA INC is based in UNITED STATES and ranks #2 among all Citalopram importers from India by value. The company sources from 1 verified supplier in India.
TORRENT PHARMA INC sources Citalopram from 1 verified Indian supplier: TORRENT PHARMACEUTICALS LIMITED ($7.9M, 100.0%). This is based on 177 customs records.
TORRENT PHARMA INC ranks #2 among 736 Citalopram importers from India with a 2.8% market share. The top 3 importers are YUSEN LOGISTICS BENELUX BELGIUM ($8.9M), TORRENT PHARMA INC ($7.3M), LEK S.A. ($4.1M). TORRENT PHARMA INC processed 177 shipments from UNITED STATES.
TORRENT PHARMA INC also imports these cns & psychiatric products. Each links to the detailed product page.
TORRENT PHARMA INC imports 9 products worth $41.5M. Beyond Citalopram, top products include Pantoprazole, Isosorbide, Rosuvastatin, Nystatin, Escitalopram. View the complete TORRENT PHARMA INC profile for full portfolio analysis.
Latest developments and market context
Detailed market intelligence for Citalopram — including regulatory updates, trade policy changes, and competitive landscape analysis — will be available in an upcoming update. This section will feature AI-researched insights from verified industry sources, government notifications, and market reports.
Verify import regulations and drug registration requirements with the agencies above.
Pharmaceutical Export-Import Analyst & Trade Intelligence Expert
Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.
linkedin.com/in/sureshsormareAll trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.
Access order-level details, pricing data, supplier connections, and competitive analysis for TORRENT PHARMA INC's Citalopram imports. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.
TORRENT PHARMA INC
Full Company Profile →
9 products · $41.5M total trade · 6 categories
| OTHER-CITALOPRAM TABLETS, USP 20MG (NDCNO.13668-010-05) ( CITALOPRAM HYDROBROMIDE 20MG ) NOS SIZE 1X500 TABLETS | $150.0K | 3 |
| OTHER-ESCITALOPRAM TABLETS USP 10MG (NDCNO.13668-136-01) (ESCITALOPRAM 10 MG) NOS SIZE 1 X 100 TABLETSNOS | $150.0K | 3 |
TORRENT PHARMA INC imports 101 distinct Citalopram formulations from India. The top formulation is ESCITALOPRAM TABLETS USP 20MG with 12 shipments worth $590.1K.
Drug Listing with FDA; Import Alert screening; Customs entry via FDA PREDICT system
US-specific labeling per 21 CFR 201 including NDC number, lot, expiry, dosage in English
Note: Subject to FDA Import Alerts and Automatic Detention if facility has open Form 483 observations.
Regulatory information is provided for general reference based on publicly available FDA guidelines for pharmaceutical imports. Requirements may vary by specific drug formulation, dosage form, and therapeutic classification. Importers should consult directly with FDA or qualified regulatory affairs professionals for case-specific guidance.
Government-Sourced Data
Official DGFT customs records
Transparent Methodology
Calculations fully disclosed above
Global Coverage
Exports to 101+ countries, 736+ buyers
Expert-Reviewed
Analyzed by pharmaceutical trade specialists
Verified from customs records
Access shipment-level records, supplier contacts, and formulation details for TORRENT PHARMA INC.
Request DemoView Pricing →Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports for Citalopram. For current order-level data, contact TransData Nexus.